<DOC>
	<DOCNO>NCT01787344</DOCNO>
	<brief_summary>To compare safety efficacy Botulax Inj.® ( Botulinum toxin type A , Hugel , South Korea ) Botox Inj.® ( Botulinum toxin type A , Allergan , USA ) treatment cerebral palsy child .</brief_summary>
	<brief_title>Phase III Clinical Trial `` Botulax® '' Treat Children With Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Children patient age 2years old 10years old . 2 . Patients diagnose cerebral palsy . 3 . Patients diagnose Gross Motor Function Classification System level I , II , III 4 . Patients diagnosed dynamic equinus foot deformity 5 . Patients agree participation sign write agreement substitute . ( Get signature child patient possible ) deformity I , II III level Gross Motor Function Classification System 1 . Patients previous injection botulinum toxin product 3 month 2 . Patients hypersensitivity history botulinum toxin product previously 3 . Patients neuromuscular junction disorder ( myasthenia gravis , Lambert Eaton syndrome , amyotrophic lateral sclerosis , etc . ) 4 . Those severe cardiovascular , kidney , liver , respiratory disease 5 . Those take anticoagulant drug bleed disorder . 6 . Pratients treatment follow drug : Anticonvulsants , tranquilizer , narcotic , aminoglycoside antibiotic , muscle relaxtants like baclofen , blocker parasympathetic nervous system , levodopa . 7 . Patients history surgery , plan surgery leg , foot , ankle . 8 . Patients evidence fix contracture regard Investigator 9 . Patients difference two legs 5cm 10 . Patients severe athetoid movement 11 . Patients treatment related dynamic equinus foot deformity , alcohol injection muscle relaxant 12 . Those enrolled study within 30 day , paseed 5 time half life clinical trial drug . 13 . Patients possibility take prevent drug 14 . Subjects eligible study base investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Other Infantile Cerebral Palsy</keyword>
</DOC>